Andreas Schneeweiss1, Julia Seitz2, Katharina Smetanay2, Florian Schuetz2, Dirk Jaeger3, Andreas Bachinger4, Markus Zorn5, Hans-Peter Sinn6, Frederik Marmé2. 1. National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany andreas.schneeweiss@med.uni-heidelberg.de. 2. National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany. 3. National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany. 4. Biometrics Department, ClinAssess GmbH, Leverkusen, Germany. 5. Central Laboratory, University Hospital Heidelberg, Heidelberg, Germany. 6. Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Abstract
AIM: To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC). PATIENTS AND METHODS: Forty-four patients with progressive MBC were prospectively treated with nab-paclitaxel. Expression of SPARC in tumor cells was assessed by an immunoreactive score, integrating staining intensity and percentage of positive tumor cells; expression in stroma based on staining intensity. SPARC serum levels were determined before 1st and 2nd cycle of nab-paclitaxel and at progression. By applying several cut-offs the association between SPARC expression or serum levels and clinical end-points was analyzed. RESULTS: No clear association between expression of SPARC in primary or metastatic tumor tissue or in serum and any clinical end-point could be detected regardless of the various cut-offs applied. CONCLUSION: Efficacy of nab-paclitaxel in MBC does not seem to be associated with expression of SPARC in tumor tissues or serum. Copyright
AIM: To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC). PATIENTS AND METHODS: Forty-four patients with progressive MBC were prospectively treated with nab-paclitaxel. Expression of SPARC in tumor cells was assessed by an immunoreactive score, integrating staining intensity and percentage of positive tumor cells; expression in stroma based on staining intensity. SPARC serum levels were determined before 1st and 2nd cycle of nab-paclitaxel and at progression. By applying several cut-offs the association between SPARC expression or serum levels and clinical end-points was analyzed. RESULTS: No clear association between expression of SPARC in primary or metastatic tumor tissue or in serum and any clinical end-point could be detected regardless of the various cut-offs applied. CONCLUSION: Efficacy of nab-paclitaxel in MBC does not seem to be associated with expression of SPARC in tumor tissues or serum. Copyright
Authors: Paul K Paik; Rachel K Kim; Linda Ahn; Andrew J Plodkowski; Ai Ni; Mark T A Donoghue; Philip Jonsson; Miguel Villalona-Calero; Kenneth Ng; Daniel McFarland; John J Fiore; Afsheen Iqbal; Juliana Eng; Mark G Kris; Charles M Rudin Journal: Clin Cancer Res Date: 2020-01-09 Impact factor: 12.531
Authors: N V Rajeshkumar; Shinichi Yabuuchi; Shweta G Pai; Zeen Tong; Shihe Hou; Scott Bateman; Daniel W Pierce; Carla Heise; Daniel D Von Hoff; Anirban Maitra; Manuel Hidalgo Journal: Br J Cancer Date: 2016-07-21 Impact factor: 7.640